Curcumin effects on myeloperoxidase, interleukin-18 and matrix metalloproteinase-9 inflammatory biomarkers in patients with unstable angina: A randomized clinical trial

Document Type: Original Research Article

Authors

1 Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

2 Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran.

3 Department of Cardiology, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

4 Department of Clinical Persian Pharmacy, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

5 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

6 Department of Pharmacology and Toxicology, School of Pharmacy, Baqiyatallah University of Medical Sciences, Tehran, Iran.

7 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

8 Department of Internal Medicine, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Abstract

Objective: Inflammation along with oxidative stress plays an important role in the development, progression, instability and rupture of coronary atherosclerotic plaques. Several studies introduced curcumin (diferuloylmethane) as a wonderful chemical in Curcuma longa (turmeric) with appropriate anti-inflammatory and antioxidant effects. The effect of curcumin on inflammatory biomarkers was assessed in several clinical trials. This study was designed to evaluate the effect of curcumin on three pro-inflammatory biomarkers in patients with unstable angina.
Materials and Methods: Forty patients with unstable angina who met the inclusion criteria, participated in this double-blind randomized clinical trial. Patients were randomly divided into two groups. The patients in the treatment group received nanocurcumin 80 mg per day for 5 days and the control group received placebo 80 mg per day for five days. Blood samples were obtained before the administration, and also 1, 2 and 4 days after taking the treatment. Serum concentrations of Myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and interleukin 18 (IL-18) biomarkers were measured by ELISA.
Results: There was no significant difference in concentration of these biomarkers before the administration and 1, 2 and 4 days after the start of the trial, between the two groups; however, the concentration of IL-18 on the first day significantly varied between the groups.
Conclusion: Based on the findings of this study, administration of nanocurcumin capsules at the dose of 80 mg per day for 5 days, did not significantly decrease inflammatory biomarkers in patients with unstable angina.

Keywords

Main Subjects


Aggarwal BB, Harikumar KB. 2009. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol, 41: 40-59.

Aggarwal BB, Sundaram C, Malani N, Ichikawa H. 2007. Curcumin: the Indian solid gold. Adv Exp Med Biol, 595: 1-75.

Alique M, Luna C, Carracedo J, Ramírez R. 2015. LDL biochemical modifications: a link between atherosclerosis and aging. Food Nutr Res, 59: 29240.

Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, Sung B, Tharakan ST, Misra K, Priyadarsini IK, Rajasekharan KN, Aggarwal BB. 2008. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol, 76: 1590-1611.

Apple FS, Wu AH, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. 2005. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem, 51: 810-824.

Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, Simoons ML, Hamm CW, Investigators C. 2003. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 108: 1440-1445.

Basnet P, Skalko-Basnet N. 2011. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules, 16: 4567-4598.

Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L, AtheroGene I. 2003. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 107: 1579-1585.

ńĆejková S, Králová-Lesná I, Poledne R. 2016. Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development. Cor et Vasa, 58: 419-425.

Foncea R, Carvajal C, Almarza C, Leighton F. 2000. Endothelial cell oxidative stress and signal transduction. Biol Res, 33: 86-96.

Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 15: 195-218.

Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci, 65: 1631-1652.

Henrotin Y, Gharbi M, Dierckxsens Y, Priem F, Marty M, Seidel L, Albert A, Heuse E, Bonnet V, Castermans C. 2014. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med, 14: 159.

Hiller O, Lichte A, Oberpichler A, Kocourek A, Tschesche H. 2000. Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J Biol Chem, 275: 33008-33013.

Hulthe J, McPheat W, Samnegård A, Tornvall P, Hamsten A, Eriksson P. 2006. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independentlyof C-reactive protein and IL-6. Atherosclerosis, 188: 450-454.

Libby P. 2000. Changing concepts of atherogenesis. J Intern Med, 247: 349-358.

Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis. Circulation, 105: 1135-1143.

Lin SS, Lai KC, Hsu SC, Yang JS, Kuo CL, Lin JP, Ma YS, Wu CC, Chung JG. 2009. Curcumin inhibits the migration and invasion of human A549 lung cancer cells through the inhibition of matrix metalloproteinase-2 and -9 and Vascular Endothelial Growth Factor (VEGF). Cancer Lett, 285: 127-133.

Lu H, Ouyang W, Huang C. 2006. Inflammation, a key event in cancer development. Mol Cancer Res, 4: 221-233.

Lucas SM, Rothwell NJ, Gibson RM. 2006. The role of inflammation in CNS injury and disease. Br J Pharmacol, 147: 232-240.

Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. 2001. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaqueinstability. Circulation, 104: 1598-1603.

Priyadarsini KI. 2014. The chemistry of curcumin: from extraction to therapeutic agent. Molecules, 19: 20091-20112.

Rosso R, Roth A, Herz I, Miller H, Keren G, George J. 2005. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol, 98: 45-48.

Saja K, Babu MS, Karunagaran D, Sudhakaran PR. 2007. Anti-inflammatory effect of curcumin involves downregulation of MMP-9 in blood mononuclear cells. Int Immunopharmacol, 7: 1659-1667.

Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM , Pirmohamed MGescher AJSteward WP. 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res, 10: 6847-6854.

Sokolove J, Lepus CM. 2013. Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations. Ther Adv Musculoskelet Dis, 5: 77-94.

Sprague AH, Khalil RA. 2009. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol, 78: 539-552.

Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Bolger G, Helson L, Wolzt M. 2015. Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther, 53: 54-65.

Swarnakar S, Ganguly K, Kundu P, Banerjee A, Maity P, Sharma AV. 2005. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem, 280: 9409-9415.

ZakynthinosE, Pappa N. 2009. Inflammatory biomarkers in coronary artery disease. J Cardiol, 53: 317-333.

Zhou H, Beevers CS, Huang S. 2011. The targets of curcumin. Curr Drug Targets, 12: 332-347.